Antioxidant effects of immunomodulators in patients with recurrent pyelonephritis

  • M. Kolesnyk SI «Institute of Nephrology NAMS of Ukraine»
  • L. Korol SI «Institute of Nephrology NAMS of Ukraine»
  • N. Stepanova SI «Institute of Nephrology NAMS of Ukraine»
  • V. Driianska SI «Institute of Nephrology NAMS of Ukraine»
  • L. Migal SI «Institute of Nephrology NAMS of Ukraine»
  • V. Savchenko SI «Institute of Nephrology NAMS of Ukraine»
Keywords: immunomodulators, reccurent pyelonephritis, oxidative stress, cytokines, treatment.

Abstract

The purpose of our work was to investigate the effect of immunomodulatory medicines on the intensity of oxidative stress (OS), the cytokines level and the activity of renospecific enzymes in patients with recurrent pyelonephritis (rPN).

Methods. A prospective, randomized, open-label study involved of 100 women aged 33.4 ± 8.8 year old. According to the sensitivity of the detected pathogens all patients received antibacterial therapy for two weeks. Along with the main course of antibiotic therapy, 25 patients were assigned Sodium nucleinate at a dose of 0.25 g 4 times per day during 14 days, 18 patients were prescribed Galavit intramuscularly 2 ml per dayfor 10 days, and 27patients were prescribed Proteflazid according to the manufacturer’s instructions. The comparison group consisted of 30 women with rPN who received antibiotic therapy exclusively.Women were screened before and after the treatment. The content of malondialdehyde (MDA), ceruloplasmin (CP), transferrin (TF) and sulfhydryl groups (SH-groups) were determined in the blood by colorimetric method. Oxidative stress index (OSI) was calculated. The concentration of interleukins (IL) -1f, -4, -8, -10, -17, tumor necrosis factor a (TNF-a), transforming growth factor f (TGF-f), monocytic chemoactive protein-1 (MCP-1) and interferon y (IFN-y) were analyzed in the blood of the women using an ELISA. To evaluate the functional state of the renal parenchyma the activity of tubular lysosome enzymes a total f-N-acetylhexosaminidase and f-galactosidase were determined in urine.

Results. The use of Sodium nucleinate decreased of the OS activity by reducing MDA level (p <0.001) and increasing the concentration of CP (p < 0.03). The serum levels ofIL-4 (p = 0.007), lL-17 (p = 0.04), TGF-f (p = 0.02) and MCP-1 (p = 0.03) were decrease. The use of Galavit contributed to a statistically significant decrease in the concentration of TNF-a (p <0.001), IL-8(p <0.001), IFN-y (p = 0.001) and TGF-f (p <0.001). The administration of Proteflazid resulted in a decrease in the concentrations of IL-8 and IFN-y, with a decrease in OSI (p =0.04) compared to pre-treatment. All applied immunomodulators partially reduced the activity of renospecific enzymes markers of kidney damage.

Conclusions. The use of immunomodulators in the complex therapy of patients with rPN contributes to the partial normalization of functional activity of immune system by the decreasing ofthe production ofcytokines as its mediators and the reducing ofthe OS intensity.

Downloads

Download data is not yet available.

References

Kolesnyk M, Stepanova N, Kruglikov V, Rudenko A. The etiological spectrum and antibiotic resistance pattern of bacteria causing uncomplicated urinary tract infections: a ten-year surveillance study (2005- 2015). Ukr.J.Nephr.Dial. 2016;№1(49):39-41. [In Ukrainian]. doi: 10.31450/ukrjnd.1(49).2016.02

Kolesnyk M, Stepanova N, Driyanskaya V, Rudenko A, Kruglikov V, Lebid L. Recurrent urinary tract infections: еtiological structure and current concept of the pathogenesis. J.Nat.Acad.Med.Sc. 2013; 19 (2):194-204. [In Ukrainian].

Kolesnyk M, Stepanova N, Korol L, Romanenko O, Mygal L. Prediction of recurrent pyelonephritis by an index of oxidative stress. Lik Sprava. 2014;(9- 10):81-8. [In Ukrainian]. PMID: 26492781

Driyanska  VE,  Drannik  GN,   Stepanova   NM, Lebed LO, Kruglikov VT, Driyanska VV, et al. Positive effects of modern immunocorrection according to the  analysis of cytokines and slpi in patients with pyelonephritis. Lik Sprava. 2014;(12):45-56. [In Ukrainian]. PMID: 26638467

Miyata T, Eckardt K-U, Nangaku M. Studies of Renal Disorders. Berlin: Springer-Verlag GmbH; 2011. 830 p. doi: 10.1007/978-1-60761-857-7.

Korol LV. Mekhanizmy rozvytku oksydatyvnoho stresu pry zapalnykh protsesakh v nyrkakh ta shl- iakhy yoho korektsii [dysertatsiia v Interneti]. Kyiv: nats. un-t im. Tarasa Shevchenka; 2017. Dostupno: http://scc.univ.kiev.ua/upload/iblock/b17/dis_ Korol%20L._new.pdf [In Ukrainian].

Putri AY, Thaha M. Role of oxidative stress on chronic kidney disease progression. Acta.Med. Indones. 2014;46(3):244-52.

Morozova OL, Morozov DA, Zaharova  NB. Prichinyi i klyuchevyie zvenya patogeneza lokal- nogo vospaleniya v mochevyivodyaschih putyah u detey s obstruktivnyimi uropatiyami. Pediatriya: zhurnal  im.  G.  N.  Speranskogo.  2014;93(2):117-123. [In    Russian].   https://pediatriajournal.ru/ archive?show=334&section=3961

Massy ZA, Stenvinkel P, Drueke TB. The role of oxidative stress in chronic kidney disease. Semin. Dial. 2009;22(4):405-8. doi: 10.1111/j.1525- 139X.2009.00590.x.

Gaĭseniuk FZ,  Driianskaia VE, Drannik GN. Proinflammatory cytokines in patients with py- elonephritis. Lik Sprava. 2013;(6):32-7. [In Ukrainian].  PMID: 25510086

Kolesnyk MO, Driianska VYe, Drannik HM, Haiseniuk FZ, Rudenko MIu, Stepanova NM, Lavrenchuk OV, Savchenko BC. Effects of immu- nocorrection on the state of cytokines and SLPI in patients with pyelonephritis. Ukr.J.Neph.Dial. 2014;№1(41):19-29. [In Ukrainian]. doi: https:// doi.org/10.31450/ukrjnd.1(41).2014.04

Andrijuk LV. Vid nuklei’novyh kyslot do pre- paratu Nuklei’nat natriju. Nov med i farm. 2007;14(220):16-20. [In Ukrainian].

Ershov FI, Ospelnikova TP, Kudryashova IP. Primenenie tsikloferona pri hronicheskom pielone- frite: dinamika pokazateley interferonovogo statusa. Terapevticheskiy arhiv. 2011;6:33-5. [In Russian].

Buryak VN, Mahmutov RF, Poshehonova YuV, Babich VL, Vihovskaya NV. Immunokorrigi- ruyuschaya terapiya pri hronicheskom pielonefrite v detskom vozraste. Sovremennaya pediatriya. 2013; 5(53):186-91. [In Russian].

Gorelov AI, Simbirtsev AS, Serezhenkov AV, Petrov AV Immunoterapiya patsientov s hroniches- kim pielonefritom v aktivnoy faze  vospaleni- ya. Vestnik Sankt-Peterburgskogo universiteta. 2014;11(3):118-24. [In Russian].

Lavrenchuk OV. Immunoreabilitatsiya detey s hronicheskim retsidiviruyuschim pielonefritom. Sovremennaya pediatriya. 2015;1(65):120-5. [In Russian]. doi 10.15574/SP.2015.65.120.

Parahonskiy AP, Timofeev VA. Patogeneticheskoe obostnovanie primeneniya immunomodulyatorov pri patologii pochek. Sovremennyie naukoemkie tehnologii. 2005;1:114-5. [In Russian].

Zemskov AM, Naraeva NYu, Deeva YuA, Startseva SV, Zhurihina II,Shabanov VG. Primenenie differen- tsirovannoy immunoterapii v lechenii zabolevaniy mochevyidelitelnoy sistemyi. Nauchno-meditsinskiy vestnik tsentralno Chernozemya. 2013;51:48-51. [In Russian].

Usovetskiy IA. Primenenie novogo immunomodu- lyatora Galavita v lechenii urogenitalnyih infektsiy. Ter.Medica. 2004;2:45-7. [In Russian].

Shatohin MN, Teodorovich OV, Chirkov SN. Sovremennyie aspektyi primeneniya immunomod- ulyatorov v urologicheskoy praktike. Urologiya i nefrologiya. 2013;1:38-42. [In Russian].

Proteflazid. Informatsionnyie materialyi po svoyst- vam i metodikam primeneniya. K., 2002. 69 р. [In Russian].

Shpot EV. Primenenie immunomodulyatora Polioksidoniy pri hronicheskih vospalitelnyih zabo- levaniyah mochepolovyih organov. Effektivnaya farmakoterapiya.  Urologiya i nefrologiya. 2012;5:14-21. [In Russian].

Mavrodiy VM, Lyubchak AM. Vedenie bolnyih s hronicheskim pielonefritom. Praktykujuchyj likar. 2015;3:44-8. [In Russian].

Narovlyanskiy AN, Ershov FI, Gintsburg AP. Interferonyi: perspektivnyie napravleniya issledo- vaniy. Immunologiya. 2013;3:168-71. [In Russian].

Korol LV, Migal LYa, Stepanova NM. Intensity of oxidative stress and activity of angionetsin convert- ing enzyme in blood of patients with uncomplicated pyelonephritis. Ukr. Biochem. J. 2017;89(2):99- 105. doi: 10.15407/ubj89.02.099.

Korol’ LV, Mygal’ LJa, vynakhidnyky; DU “In-t nefrolohii AMN Ukrainy”, patentovlasnyk. Sposib integral’noi’ ocinky antyoksydantnoi’ jemnosti syrovatky krovi Patent Ukrainy. № 113602. 2017, Opub. 10.02.2017, Bjul. № 3. [In Ukrainian].

Mygal’ LJa, Bagdasarova IV, Serbina IJe, Kindij TV. Lisozomna enzymuriia yak kryterii dysfunktsii proksymalnykh kanaltsiv nyrok u ditei pry prohre- suvanni hlomerulonefrytu. Perynatologija ta pedi- atrija. 2003;3:39-41. [In Ukrainian].

Karpenko VS, Kolesnikov GF, Petrun NM. Funktsionalnaya diagnostika v urologii i nefrologii K.: Zdorov’ya, 1977. Р. 63-70. [In Russian].

Sutariya B, Jhonsa D, Saraf MN. TGF-β: the con- necting link between nephropathy and fibrosis. Immunopharm.Immunotox. 2016;38(1):39-49. doi:10.3109/08923973.2015.1127382. PMID: 26849902.

Humm A, Fritsche E, Steinbacher S, Huber R. Crystal structure and mechanism of human L-arginine:glycine amidinotransferase : a mito- chondrial enzyme involved in creatine biosynthe- sis. EMBO J. 1997;16(12):3373-85. doi: 10.1093/ emboj/16.12.3373. PMID 9218780

Fergyuson MA, Vaykar SS. Ustanovlennyie i vnov predlagaemyie markeryi pochek. Klinicheskaya laboratornaya diagnostika. 2013;11:3-11. [In Russian].

Mohkam M, Ghafari A. The Role of Urinary N-acetyl- beta-glucosaminidase in Diagnosis of Kidney Diseases. Ped. Nephrology. 2015;3(3):84-91.

Stashevskа NV, Korol LV, Myhal LJa, Stepanova NM. The role of gut indigenous microbiota in the devel- opment of oxidative stress in women with recurrent pyelonephritis.   Ukr.J.Neph.Dial.   2017;1(53):31-5 [In Ukrainian]. doi https://doi.org/10.31450/ ukrjnd.1(53).2017.05

 


Abstract views: 238
PDF Downloads: 115
Published
2018-06-17
How to Cite
Kolesnyk, M., Korol, L., Stepanova, N., Driianska, V., Migal, L., & Savchenko, V. (2018). Antioxidant effects of immunomodulators in patients with recurrent pyelonephritis. Ukrainian Journal of Nephrology and Dialysis, (2(58), 18-28. https://doi.org/10.31450/ukrjnd.2(58).2018.04

Most read articles by the same author(s)

1 2 > >>